Showing 5 of 48 posts
August 22, 2019 | Blogs
In 2017, the first therapy designed to genetically modify patients’ own T-cells to attack cancer was FDA-approved, but are CAR T-cell therapies close to meeting the remaining needs of patients? CBPartners' Cell and Gene Therapy Center of Excellence investigates the current challenges and limitations of this therapy.
August 17, 2019 | Blogs
Do Cutting-Edge One-Time Treatments Need Equally Innovative Outcomes or Annuity Based Payment Models?
Eventual success of innovative payment models broadening access and realising the promise of cutting-edge, curative gene and cell therapies will depend on the ability of manufacturers and payers to compromise on risk sharing. Manufacturers of novel one-time treatments can increase the likelihood of successful negotiations by following a few guiding principles - CBPartners' Cell and Gene Therapy Center of Excellence analyse the future success of innovative payment models.
August 13, 2019 | Blogs
Since the Chinese government brought a deluge of reforms to their pharmaceutical sector in 2018, it is no surprise 2019 is shaping up to be another game-changing year. CBPartners' Asia-Pacific Center of Excellence delivered insights about the evolving NRDL in China, as well as strategic considerations for pharmaceutical manufacturers.
July 24, 2019 | Blogs
July 10, 2019 | Blogs, Infographics
The Impact of Central and Eastern European (CEE) International Reference Pricing (IRP) Policy Changes
Changes to IRP policies in the CEE markets can impact pricing across the EU region and should therefore be closely monitored particularly as the list price in a given CEE market may be re-referenced by other global markets.